Business Context and Reporting Period
This Form 8-K was filed by Sonoma Pharmaceuticals, Inc. on June 4, 2020, reporting events occurring on May 29, 2020. The company is currently consolidating corporate functions to its Woodstock, Georgia offices and recently closed its Seattle, Washington location as part of a strategy to achieve and sustain profitability.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. Specific financial data disclosed relates solely to the executive separation agreement:
- Separation Payment: $204,000 in cash.
- Accrued PTO: $26,600.
- Healthcare Reimbursement: Coverage for the executive and dependents for up to 12 months.
- Equity: All outstanding time-based equity awards fully vested.
- Consulting Fee: $200 per hour for transition services.
Material Changes
The primary material change reported is the departure of Dr. Robert Northey as Executive Vice President of Research and Development on May 29, 2020. This action is part of the broader consolidation of operations following the closure of the Seattle office. Dr. Northey, who served for 17 years, has transitioned to a consultant role to assist with the transition to a new R&D department.
Guidance, Outlook, and Risks
Management's outlook focuses on the goal of achieving and sustaining profitability through operational consolidation. The filing includes standard forward-looking statements regarding future activities and strategies, noting that actual results may differ due to risks and uncertainties discussed in the company's Annual Report on Form 10-K. No specific financial guidance or revenue projections were provided in this report.
Investor Verification Checklist
- Verify the total immediate cash outflow of $230,600 ($204,000 separation + $26,600 PTO) and its impact on current liquidity.
- Confirm the status of the new Research and Development department leadership following Dr. Northey's departure.
- Review the company's most recent Form 10-K for detailed financial health, debt levels, and cash runway.
- Assess the timeline and cost implications of the ongoing office consolidation in Georgia.